Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.21.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2020

3,869,896

$

3.61

Granted

919,012

2.70

Vested

(548,040)

4.17

Non-vested at September 30, 2021

4,240,868

$

3.34

Summary of stock option award activity

The following table summarizes stock option award activity for the nine months ended September 30, 2021:

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2020

220,000

$

3.20

8.04

Granted

50,000

2.85

Outstanding as of September 30, 2021

270,000

$

3.14

7.69

Vested and exercisable as of September 30, 2021

50,000

$

2.56

7.69

Summary of stock options assumptions used

For the Nine Months Ended September  30,

 

    

2021

    

2020

 

Risk-free interest rate

 

1.04% - 1.50

%

0.65% - 1.02

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

100.65% - 102.71

%

101.27% - 104.60

%

Summary of warrant activities

A summary of warrant activities for the nine months ended September 30, 2021 is presented below:

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2020

57,515

$

5.39

1.22

Expired

(44,324)

7.00

Outstanding as of September 30, 2021

13,191

$

0.00

4.08

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 ($ in thousands):

For the three months ended September 30, 

For the nine months ended September 30, 

    

2021

    

2020

    

2021

    

2020

Research and development

$

161

$

157

$

480

$

462

General and administrative

 

618

 

568

 

1,839

 

1,633

Total stock-based compensation expense

$

779

$

725

$

2,319

$

2,095